Innoviva, Inc.: financial analysis
Ratios worked out from 10 fiscal years of Innoviva, Inc.'s statements, compared with 665 companies in Biotechnology.
Innoviva, Inc. scorecard#
Passes 21 of the 26 checks that could be worked out: strongest in valuation (6 of 6), weakest in shareholder returns (1 of 3). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation6 of 6
- ✓P/E below its peers' median7.6×P/E 7.6× against Biotechnology's median of 17.5×.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median3.4×Price to sales 3.4× against Biotechnology's median of 8.8×.
- ✓Free cash flow yield above 5%13.3%Free cash flow is 13.3% of the market value.
- ✓Earnings yield above the 10-year Treasury yield13.2%Earnings yield 13.2% against the 10-year Treasury's 4.92% on 2026-11-20.
- ✓The price assumes slower growth than the last three years'-7.7%The price assumes -7.7% a year for ten years; revenue grew 7.5% a year over the last three.
Growth3 of 6
- ✓Revenue grew in the newest year14.7%Revenue up 14.7% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years7.5%7.5% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median7.5%7.5% a year against Biotechnology's median of 12.9% (181 companies).
- ✓Earnings per share grew in the newest year3.30 vs 0.36Diluted EPS 3.30 in fiscal 2025 against 0.36 the year before (report's currency).
- ✗Net income higher than five years earlier$271 M$271 M in fiscal 2025 against $294 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability5 of 5
- ✓Profitable in the newest year$271 MNet income $271 M in fiscal 2025.
- ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median39.8%39.8% against Biotechnology's median of -60.5% (243 companies).
- ✓Return on equity above 15%29.1%29.1% in fiscal 2025.
- ✓Return on invested capital above 10%17.9%17.9% in fiscal 2025.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health6 of 6
- ✓Short-term assets cover short-term liabilities14.6×Current ratio 14.64 at the end of fiscal 2025.
- ✓Debt below equity0.2×Debt to equity 0.22 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $293 M at the end of fiscal 2025.
- ✓Operating income covers interest five times9.8×Operating income 9.8 times interest in fiscal 2025.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- ✓Altman Z-score outside the distress zone3.22Z-score 3.22 (safe zone) for fiscal 2025.
Shareholder returns1 of 3
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year14.2%Diluted shares up 14.2% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.3%Dividends and buybacks were 0.3% of the market value.
- ✓Free cash flow covers dividends and buybacks$196 MFree cash flow $196 M against $5 M paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Free cash flow has been positive 11 years in a row.
- More cash than debt: net cash of $293 million.
Worth a look
- The share count rose 14.2% in the year.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseyes
- Cash from operations exceeds profitno
- Long-term debt fell against assetsyes
- Current ratio roseyes
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.41 | × 1.2 | 0.50 |
| Retained earnings to assets | 0.17 | × 1.4 | 0.23 |
| Operating income to assets | 0.10 | × 3.3 | 0.33 |
| Market value to liabilities | 3.18 | × 0.6 | 1.91 |
| Revenue to assets | 0.25 | × 1 | 0.25 |
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 74.8% | 82.6% | 79.3% | — | — | 74.8% | 50% | |
| Operating margin | 39.8% | 46.5% | 36.7% | — | 95.7% | -60.5% | 95% | |
| Net margin | 65.9% | 6.5% | 57.9% | 66.5% | 94.1% | -68.9% | 97% | |
| Return on equity | 29.1% | 3.4% | 29.0% | 44.9% | 77.3% | -61.0% | 96% | |
| Return on assets | 18.5% | 1.8% | 14.5% | 20.4% | 38.3% | -44.4% | 96% | |
| Return on invested capital | 17.9% | 13.3% | 12.8% | — | 48.3% | 17.3% | 53% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 14.7% | 15.5% | -6.3% | -15.5% | 16.4% | 15.8% | 48% | |
| Revenue growth, 3 years a year | 7.5% | -2.9% | -2.7% | 8.3% | 14.5% | 12.9% | 43% | |
| Revenue growth, 5 years a year | 4.1% | 6.6% | 3.5% | 8.8% | 24.0% | 15.4% | 29% | |
| Net income growth | — | -87.0% | -18.4% | -40.3% | 25.5% | 10.1% | — | |
| Earnings per share growth | 816.7% | -83.6% | -7.2% | -17.4% | 42.1% | 7.6% | 100% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | 0.22× | 0.37× | 0.66× | 0.79× | 0.95× | 0.26× | 52% | |
| Net debt | $-293 M | $-49 M | $253 M | $153 M | $193 M | $-16 M | 93% | |
| Net debt to EBITDA | — | — | — | — | 0.50× | 0.05× | — | |
| Interest cover | 9.80× | 7.51× | 5.94× | — | 19.67× | -22.77× | 96% | |
| Current ratio | 14.64× | 2.35× | 9.03× | 3.29× | 53.99× | 4.39× | 90% | |
| Equity share of assets | 71.7% | 53.1% | 54.3% | 45.9% | 44.8% | 64.7% | 57% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $196 M | $188 M | $141 M | $202 M | $364 M | $-40 M | 96% | |
| Free cash flow margin | 47.6% | 52.5% | 45.3% | 60.9% | 92.8% | -61.5% | 98% | |
| Cash conversion | 72.6% | 806.7% | 78.5% | 91.6% | 98.6% | 72.6% | 50% | |
| Capital spending share of revenue | 0.3% | 0.1% | 0.1% | 0.0% | 0.0% | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.28× | 0.28× | 0.25× | 0.31× | 0.41× | 0.26× | 52% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Return on invested capital
- Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Net debt to EBITDA
- Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Dividend payout
- Dividends paid as a share of net income. Only when the year was profitable.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).